Pegylated darbepoetin alfa biosimilar - Merck

Drug Profile

Pegylated darbepoetin alfa biosimilar - Merck

Alternative Names: Erythropoietin biosimilar - Merck; MK-2578; Recombinant PEG-erythropoietin biosimilar - Merck

Latest Information Update: 28 Aug 2013

Price : $50

At a glance

  • Originator GlycoFi
  • Developer Merck & Co
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 28 Aug 2013 Discontinued - Phase-II for Anaemia in Italy (SC)
  • 28 Aug 2013 Discontinued - Phase-II for Anaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top